Current Opinion in Gastroenterology最新文献_第4页

Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects? 胰高血糖素样肽激动剂及其在短肠综合征中的应用——副作用如何？

IF 2.8 3区医学

Current Opinion in Gastroenterology Pub Date : 2026-05-01 Epub Date: 2026-03-20 DOI: 10.1097/MOG.0000000000001169

Lucy Gorard, Megan Boucher, Charlotte Rutter

{"title":"Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects?","authors":"Lucy Gorard, Megan Boucher, Charlotte Rutter","doi":"10.1097/MOG.0000000000001169","DOIUrl":"10.1097/MOG.0000000000001169","url":null,"abstract":"Purpose of review: This review summarizes recent evidence on the use of glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) agonists in the management of short bowel syndrome (SBS), with a focus on emerging therapies and real-world experience. It evaluates their impact on intestinal adaptation, safety, and future clinical potential.Recent findings: GLP-2 agonists such as teduglutide continue to demonstrate improvements in intestinal absorption resulting in reductions in parenteral support (PS) requirements and improved quality of life. Clinical trials report that newer long-acting agents, such as apraglutide and glepaglutide, allow less frequent dosing with a reduction in PS and structural intestinal changes on imaging. Safety profiles remain favourable, with gastrointestinal symptoms, fluid balance issues, gallbladder events and injection-site reactions reported most frequently. GLP-1 agonists show promise in slowing transit time and offer an area for further research.Summary: While GLP-2 agonists shape the current landscape of SBS management, GLP-1 based therapies may complement future treatment strategies offering the potential to reduce or even eliminate dependence on PS. Continued long-term studies and registry data are essential to optimize patient selection, safety monitoring, and personalized use of GLP agonists.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"201-207"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The utility of albumin in cirrhosis: established benefits and unanswered questions. 白蛋白在肝硬化中的应用：已确定的益处和未解决的问题。

IF 2.8 3区医学

Current Opinion in Gastroenterology Pub Date : 2026-05-01 Epub Date: 2026-01-29 DOI: 10.1097/MOG.0000000000001155

Karim Besir, Don C Rockey

{"title":"The utility of albumin in cirrhosis: established benefits and unanswered questions.","authors":"Karim Besir, Don C Rockey","doi":"10.1097/MOG.0000000000001155","DOIUrl":"10.1097/MOG.0000000000001155","url":null,"abstract":"Purpose of review: Albumin plays a central role in maintaining circulatory and endothelial homeostasis through its oncotic and nononcotic effects. In cirrhosis, reduced concentration and impaired function of albumin contribute to circulatory derangements, renal dysfunction, and infection risk. While albumin is firmly established in certain settings such as spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), and large-volume paracentesis (LVP), its broader use in cirrhosis remains controversial and incompletely defined. We aim to integrate up to date guidance on the use of albumin in cirrhosis, and to highlight areas where evidence remains limited or evolving.Recent findings: Evidence from randomized trials and meta-analyses highlights both established and emerging roles of albumin in cirrhosis. Albumin has demonstrated clear benefit after LVP, where it reduces postprocedural circulatory dysfunction, renal impairment, and hyponatremia compared with other plasma expanders. In HRS, albumin serves as an indispensable therapeutic backbone, enhancing the efficacy of vasoconstrictors and improving rates of renal reversal, yet its independent role remains incompletely defined. In SBP, co-administration of albumin with antibiotics reduces renal failure and improves short-term survival, establishing it as standard of care. In acute kidney injury (AKI) outside of HRS, current guidelines recommend the use of albumin as part of an initial volume challenge in many forms of AKI to aid diagnosis and potentially promote renal recovery, although the timing of its use differs among guidelines.Summary: Albumin is a cornerstone therapy in the management of decompensated cirrhosis and its clinical complications. While its role is well defined in HRS, SBP, and post-LVP, higher-quality evidence is needed to refine its use in other settings, particularly in AKI.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"42 3","pages":"114-120"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147583029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antithrombotic and management of small bowel bleeding - time to throw caution into the wind? 抗血栓治疗和小肠出血的处理——是时候不顾一切了吗？

IF 2.8 3区医学

Current Opinion in Gastroenterology Pub Date : 2026-05-01 Epub Date: 2026-02-10 DOI: 10.1097/MOG.0000000000001160

Lucia Scaramella, Agostino Cosenza, Cristina Romero-Mascarell, Luca Elli

{"title":"Antithrombotic and management of small bowel bleeding - time to throw caution into the wind?","authors":"Lucia Scaramella, Agostino Cosenza, Cristina Romero-Mascarell, Luca Elli","doi":"10.1097/MOG.0000000000001160","DOIUrl":"10.1097/MOG.0000000000001160","url":null,"abstract":"Purpose of review: Small bowel bleeding (SBB) represents a significant diagnostic and therapeutic challenge. The use of antithrombotic therapy (oral anticoagulants and antiplatelet agents) has led to an increase in gastrointestinal bleeding events, particularly in the small bowel. The endoscopic management of SBB in patients receiving antithrombotic therapy remains a clinical dilemma . This review explores the current perspectives on the endoscopic management of SBB in patients receiving antithrombotic therapy and discusses whether the traditional cautions approach should be reconsidered.Recent findings: Recent studies confirmed a higher diagnostic yield of small bowel capsule endoscopy (SBCE) in patients administered with antithrombotic agents, and an increased prevalence of SBB from vascular lesions. Device-assisted enteroscopy (DAE) is the reference standard for endoscopic therapy; however, rebleeding rate remains high.Summary: Endoscopic management of SBB in patients receiving antithrombotic therapy remains suboptimal. Maintenance of therapy increases the diagnostic yield of SBCE; however, guidelines recommend to discontinue the therapy before DAE. This mismatch highlights a substantial disconnection between evidence and clinical practice. Prospective studies and expert consensus are needed to optimize outcomes in this population.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"146-153"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune-related enteropathy. 几种肠病。

IF 2.8 3区医学

Current Opinion in Gastroenterology Pub Date : 2026-05-01 Epub Date: 2026-03-05 DOI: 10.1097/MOG.0000000000001162

Kimberley Butler, Hugo A Penny, Foong Way David Tai

{"title":"Immune-related enteropathy.","authors":"Kimberley Butler, Hugo A Penny, Foong Way David Tai","doi":"10.1097/MOG.0000000000001162","DOIUrl":"10.1097/MOG.0000000000001162","url":null,"abstract":"Purpose of review: Immune-related enteropathies (IREs) represent a heterogeneous group of disorders characterised by immune-mediated small bowel injury. While coeliac disease is the most common cause, widespread use of small bowel endoscopy has expanded the recognition of rarer causes. This review aims to summarise recent advances in diagnosis, classification and management of IRE.Recent findings: Significant overlap exists between coeliac disease, autoimmune enteropathy, collagenous sprue, drug-induced enteropathies, common variable immunodeficiency (CVID) associated enteropathy and other IRE. A recent meta-analysis supports a no-biopsy approach in selected adults with significantly elevated IgA tissue transglutaminase levels and suspected coeliac disease. Refractory coeliac disease type II is now recognised as a low-grade intraepithelial T-cell lymphoma with a high risk of progression to enteropathy-associated T-cell lymphoma (EATL). Drug-induced enteropathies, particularly olmesartan-associated enteropathy, are increasingly detected and may mimic autoimmune enteropathy histologically. Novel therapeutic approaches, including cladribine, JAK inhibitors and biologics, have shown promise in refractory disease, although evidence is limited to small studies.Summary: IREs present substantial diagnostic and therapeutic challenges due to overlapping characteristics and variable disease course. A structured approach integrating clinical, serological and histopathological data is essential for accurate diagnosis. Early recognition and tailored management are crucial to prevent long-term complications.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"189-200"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision medicine in steatotic liver disease. 脂肪变性肝病的精准医学。

IF 2.8 3区医学

Current Opinion in Gastroenterology Pub Date : 2026-05-01 Epub Date: 2026-03-06 DOI: 10.1097/MOG.0000000000001165

Vitchapong Prasitsumrit, Vincent L Chen

{"title":"Precision medicine in steatotic liver disease.","authors":"Vitchapong Prasitsumrit, Vincent L Chen","doi":"10.1097/MOG.0000000000001165","DOIUrl":"10.1097/MOG.0000000000001165","url":null,"abstract":"Purpose of review: Discuss advances in genomics, metabolomics, and proteomics in steatotic liver disease.Recent findings: Common genetic variants in genes including PNPLA3, TM6SF2, and HSD17B13 are associated with risk of hepatic steatosis, metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD) cirrhosis, and hepatocellular carcinoma. In contrast, variants in other genes such as GCKR are strongly associated with steatosis but much more weakly associated with advanced liver disease. The cirrhosis-associated variants typically drive steatosis through reduction of lipid export from the liver, potentially highlighting this mechanism as a driver of fibrosis though not ruling out alternative pathways. Alterations in amino acids, lipids, bile acids, and other metabolites have been observed in both MASLD and ALD reflecting insulin resistance, altered bile acid metabolism, and increased fatty acid flux and de novo lipogenesis (for MASLD) or mitochondrial dysfunction (for ALD). Also seen are characteristic changes in serum/plasma protein levels reflecting fibrosis, systemic inflammation, and hepatic synthetic function are also seen with MASLD and ALD. Predictive models incorporating genomics, metabolomic, and proteomic biomarkers may improve upon existing clinical models, but nearly all studies on this topic have been retrospective or post hoc.Summary: Genomics, metabolomics, proteomics, and multiomics may improve our understanding of disease pathophysiology. They may also have implications for clinical care, but further prospective studies are required to establish whether they provide sufficient benefit over clinical biomarkers to be routinely used.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"42 3","pages":"121-128"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147583108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasma exchange in acute liver failure. 血浆置换治疗急性肝功能衰竭。

IF 2.8 3区医学

Current Opinion in Gastroenterology Pub Date : 2026-05-01 Epub Date: 2026-03-05 DOI: 10.1097/MOG.0000000000001166

Hampton B Sasser, David G Koch

{"title":"Plasma exchange in acute liver failure.","authors":"Hampton B Sasser, David G Koch","doi":"10.1097/MOG.0000000000001166","DOIUrl":"10.1097/MOG.0000000000001166","url":null,"abstract":"Purpose of review: Acute liver failure is a life-threatening condition that requires intensive medical management or liver transplant for survival. Plasma exchange has been investigated as a supportive intervention to provide a bridge to hepatic recovery or to liver transplant. This review aims to explain the physiologic rationale, provide historical context, and review recent evidence on the use of plasma exchange in acute liver failure.Recent findings: Recent studies paint a mixed picture of plasma exchange's role in the current armamentarium for the management of acute liver failure. Although multiple meta-analyses have shown a survival benefit from plasma exchange, the results from original studies published in the interim are less consistent, with some showing a survival benefit and others not. Further, the literature on this topic is quite heterogeneous with respect to baseline patient characteristics, etiologies of acute liver failure, the dose of plasma exchange administered, and the outcomes assessed. The takeaways and limitations of recent evidence will be discussed.Summary: Plasma exchange has a clear physiologic basis for use in acute liver failure, and multiple prospective studies have shown its ability to improve survival. The effectiveness of plasma exchange, however, depends on appropriate patient selection and timely initiation.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"129-135"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147357066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dietary therapy for small bowel Crohn's disease. 饮食疗法治疗小肠克罗恩病

IF 2.8 3区医学

Current Opinion in Gastroenterology Pub Date : 2026-05-01 Epub Date: 2026-01-29 DOI: 10.1097/MOG.0000000000001156

Yael Baharad, Tal Engel, Shomron Ben-Horin

{"title":"Dietary therapy for small bowel Crohn's disease.","authors":"Yael Baharad, Tal Engel, Shomron Ben-Horin","doi":"10.1097/MOG.0000000000001156","DOIUrl":"10.1097/MOG.0000000000001156","url":null,"abstract":"Purpose of review: This review highlights the emerging role of dietary interventions for Crohn's disease (CD).Recent findings: An overview of clinical data on dietary strategies for management of CD is presented, including exclusive enteral nutrition, the Crohn's disease exclusion diet (CDED) and the Mediterranean diet, among others. The methodological challenges in performing dietary randomized trials are outlined, including the difficulty in blinding, the multiple components inherent to food interventions and the heterogeneous nature of even 'similar' dietary constituents, collectively making it hard to delineate the responsible mechanism for any observed effect. We also review the data on food supplements explored for this CD treatment, such as vitamin D, omega-3 and combination curcumin-QingDai (CurQD). Novel strategies to integrate personalized nutrition with pharmacologic therapy are discussed and may ultimately improve disease control and patients' long term prognosis and quality of life. Dietary interventions as preventive measures in patients at risk of developing CD are particularly appealing, but are still backed only by association studies, thereby mandating further research before they can be strongly endorsed.Summary: Emerging evidence suggests a range of dietary interventions as potentially effective and safe strategies for management of small bowel CD.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"172-177"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Small-bowel capsule endoscopy - from clinic to couch: time to go green? 小肠胶囊内窥镜检查——从诊所到沙发：是时候走向绿色了？

IF 2.8 3区医学

Current Opinion in Gastroenterology Pub Date : 2026-05-01 Epub Date: 2026-02-13 DOI: 10.1097/MOG.0000000000001159

Ian Io Lei, Ramesh P Arasaradnam, Anastasios Koulaouzidis

{"title":"Small-bowel capsule endoscopy - from clinic to couch: time to go green?","authors":"Ian Io Lei, Ramesh P Arasaradnam, Anastasios Koulaouzidis","doi":"10.1097/MOG.0000000000001159","DOIUrl":"10.1097/MOG.0000000000001159","url":null,"abstract":"Purpose of review: Small-bowel capsule endoscopy (SBCE) has transformed small-intestine diagnostics by enabling direct, noninvasive mucosal visualization. As healthcare systems increasingly prioritize value-based and sustainable care, this review explores recent advances in SBCE, focusing on home-delivery models, telemedicine, artificial intelligence (AI), and environmental impact.Recent findings: Life-cycle analyses estimate ~20 kgCO 2 per SBCE, ~18 kgCO 2 arising from patient travel. Transitioning from hospital attendance to home-delivery models can materially reduce this footprint. Feasibility studies report high acceptability for remote delivery, teleconsultation, and decentralized reading. AI-assisted reading platforms have recently shown significant reductions in reporting time, improving workflow efficiency. Rural modelling suggests travel emissions for colon capsule endoscopy (CCE) can exceed colonoscopy (~19.2 kgCO 2 e) but fall to ~5.3 kgCO 2 e with optimized courier logistics, despite >50% follow-up endoscopy rate.Summary: SBCE now stands at the nexus of technological innovation, clinical utility, and environmental accountability. Its journey from hospital corridors to home settings exemplifies a diagnostic paradigm built on accessibility, efficiency, and ecological integrity. Realizing this vision requires multicentre trials that incorporate life cycle, cost-effectiveness, and patient-reported outcomes. The capsule of the future will not merely image the intestine - it will symbolize medicine's evolution toward intelligent, zero-waste diagnostics.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"163-171"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146198238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are we missing early pancreatic dysfunction? Expanding faecal elastase testing beyond pancreatic disease. 我们是否忽略了早期胰腺功能障碍？将粪便弹性酶测试扩展到胰腺疾病之外。

IF 2.8 3区医学

Current Opinion in Gastroenterology Pub Date : 2026-05-01 Epub Date: 2026-03-05 DOI: 10.1097/MOG.0000000000001163

Connor E M Cotton, Andrew D Hopper, David S Sanders

{"title":"Are we missing early pancreatic dysfunction? Expanding faecal elastase testing beyond pancreatic disease.","authors":"Connor E M Cotton, Andrew D Hopper, David S Sanders","doi":"10.1097/MOG.0000000000001163","DOIUrl":"10.1097/MOG.0000000000001163","url":null,"abstract":"Purpose of review: Pancreatic exocrine insufficiency (PEI) has long been associated with intrinsic pancreatic disease, yet emerging evidence shows it is under-recognized in patients with nonspecific gastrointestinal symptoms. This review summarizes prevalence data, evaluates the performance and utility of faecal elastase-1 (FE-1), highlights the co-existence of PEI with other luminal conditions, and explores the presence of early pancreatic dysfunction among a subset of patients with irritable bowel syndrome (IBS)-type symptoms. Updates from the 2025 European guidelines are discussed.Recent findings: Population studies estimate PEI prevalence at 11-21% in unselected gastroenterology cohorts. PEI is reported across coeliac disease, inflammatory bowel disease and functional gastrointestinal disorders, where overlapping symptoms can delay diagnosis. A 2025 meta-analysis of FE-1 performance demonstrated high sensitivity for moderate-severe PEI. Cohort data indicates repeat sampling can clarify borderline results. PEI may be an early marker of pancreatic dysfunction in a subset of patients with IBS-type symptoms. Identifying this group may offer opportunities for lifestyle modification with potential long-term benefit.Summary: Collectively, these findings expand the relevance of PEI beyond classical pancreatic disease. Broader, proactive FE-1 testing may allow earlier recognition, which might allow intervention at a potentially modifiable stage of pancreatic dysfunction, accepting the limitations of the test.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"154-162"},"PeriodicalIF":2.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147356763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PBC-AIH variant syndrome: emerging new terminology and a new approach to diagnosis and management. PBC-AIH变异综合征：出现的新术语和诊断和管理的新方法。

IF 2.5 3区医学

Current Opinion in Gastroenterology Pub Date : 2026-03-01 Epub Date: 2025-12-22 DOI: 10.1097/MOG.0000000000001149

Marcial Sebode, Alessio Gerussi

{"title":"PBC-AIH variant syndrome: emerging new terminology and a new approach to diagnosis and management.","authors":"Marcial Sebode, Alessio Gerussi","doi":"10.1097/MOG.0000000000001149","DOIUrl":"10.1097/MOG.0000000000001149","url":null,"abstract":"Purpose of review: This review summarizes the recent developments of one of the most controversial entities in hepatology, variant syndromes of primary biliary cholangitis (PBC) with characteristics of autoimmune hepatitis (AIH).Recent findings: Recently a consensus process was initiated to find agreement on the terminology, diagnostic criteria and treatment recommendations for patients with PBC-AIH variant syndromes. The concept and terminology of a variant syndrome, with one component of either AIH or PBC dominating over the other, is currently preferred. No single test can establish the diagnosis of a variant syndrome, only a combination of biochemical, serological and/or histological tests can support the diagnosis. If classical PBC is dominating, histology is mandatory for the diagnosis of a PBC-AIH variant syndrome. Treatment of PBC-AIH variants is based on a combination of ursodeoxycholic acid and immunosuppression. Since the prognosis of a PBC-AIH variant syndrome seems to be worse than the prognosis of classical PBC, the diagnosis of PBC-AIH must not be missed.Summary: The recent consensus process on PBC-AIH variant syndromes does not provide answers to all questions regarding this entity. Rather, it serves as a starting point for future studies to confirm or even challenge the current consensus.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"68-74"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145812173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0